Skip to content

Iodine Status and Characteristics of Papillary Thyroid Cancer

A Cross-sectional Study on Iodine Status and Characteristics of Papillary Thyroid Cancer

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06626581
Enrollment
600
Registered
2024-10-04
Start date
2024-11-01
Completion date
2026-12-31
Last updated
2024-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary Thyroid Carcinoma

Keywords

iodine status, papillary thyroid carcinoma

Brief summary

The effect of iodine on papillary thyroid cancer has been controversial for many years. The investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.

Interventions

DIETARY_SUPPLEMENTIodine excess

Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L

DIETARY_SUPPLEMENTIodine suitable

Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.

Sponsors

Shandong Provincial Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age range: 18\ 65 years old, gender not limited; * Living in the residential area for at least 5 years; * Patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer; * Complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc.

Exclusion criteria

* Pathological diagnosis of other types of thyroid cancer; * Diagnosed with other types of cancer; * There are serious comorbidities of the heart, liver, and kidneys;

Design outcomes

Primary

MeasureTime frame
Serum and urine iodine levels1 year from enrollment
TNM staging of papillary thyroid cancer3 month from enrollment

Contacts

Primary ContactQingling Guo
guoqinglingqhb@163.com+86-0531-68776375

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026